243 related articles for article (PubMed ID: 29325754)
1. A comprehensive approach for evaluating charge heterogeneity in biosimilars.
Xiao Z; Yin X; Han L; Sun B; Shen Z; Liu W; Yu F
Eur J Pharm Sci; 2018 Mar; 115():19-24. PubMed ID: 29325754
[TBL] [Abstract][Full Text] [Related]
2. Discovery and characterization of antibody variants using mass spectrometry-based comparative analysis for biosimilar candidates of monoclonal antibody drugs.
Li W; Yang B; Zhou D; Xu J; Ke Z; Suen WC
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jul; 1025():57-67. PubMed ID: 27214604
[TBL] [Abstract][Full Text] [Related]
3. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies.
Ishii-Watabe A; Kuwabara T
Drug Metab Pharmacokinet; 2019 Feb; 34(1):64-70. PubMed ID: 30600193
[TBL] [Abstract][Full Text] [Related]
4. Isolation and characterization of charge variants of infliximab biosimilar HS626.
Yuan JJ; Gao D; Hu F; Shi Y; Wu ZH; Hu CQ; Huang XD; Fang WJ; Zhang HT; Wang HB
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jan; 1162():122485. PubMed ID: 33360415
[TBL] [Abstract][Full Text] [Related]
5. QbD-guided pharmaceutical development of Pembrolizumab biosimilar candidate PSG-024 propelled to industry meeting primary requirements of comparability to Keytruda®.
Jaffar-Aghaei M; Khanipour F; Maghsoudi A; Sarvestani R; Mohammadian M; Maleki M; Havasi F; Rahmani H; Karagah AH; Kazemali MR
Eur J Pharm Sci; 2022 Jun; 173():106171. PubMed ID: 35378209
[TBL] [Abstract][Full Text] [Related]
6. Characterization of alanine to valine sequence variants in the Fc region of nivolumab biosimilar produced in Chinese hamster ovary cells.
Li Y; Fu T; Liu T; Guo H; Guo Q; Xu J; Zhang D; Qian W; Dai J; Li B; Guo Y; Hou S; Wang H
MAbs; 2016 Jul; 8(5):951-60. PubMed ID: 27050807
[TBL] [Abstract][Full Text] [Related]
7. A new CHO (Chinese hamster ovary)-derived cell line expressing anti-TNFα monoclonal antibody with biosimilar potential.
Luchese MD; Lopes Dos Santos M; Garbuio A; Targino RC; Mansueli CP; Tsuruta LR; Quintilio W; Moro AM
Immunol Res; 2018 Jun; 66(3):392-405. PubMed ID: 29855993
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic monoclonal antibodies: strategies and challenges for biosimilars development.
Calvo B; Zuñiga L
Curr Med Chem; 2012; 19(26):4445-50. PubMed ID: 22978327
[TBL] [Abstract][Full Text] [Related]
9. The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.
Brady LJ; Velayudhan J; Visone DB; Daugherty KC; Bartron JL; Coon M; Cornwall C; Hinckley PJ; Connell-Crowley L
MAbs; 2015; 7(3):562-70. PubMed ID: 25898160
[TBL] [Abstract][Full Text] [Related]
10. Glycosylation of biosimilars: Recent advances in analytical characterization and clinical implications.
Duivelshof BL; Jiskoot W; Beck A; Veuthey JL; Guillarme D; D'Atri V
Anal Chim Acta; 2019 Dec; 1089():1-18. PubMed ID: 31627805
[TBL] [Abstract][Full Text] [Related]
11. How Similar Is Biosimilar? A Comparison of Infliximab Therapeutics in Regard to Charge Variant Profile and Antigen Binding Affinity.
Beyer B; Walch N; Jungbauer A; Lingg N
Biotechnol J; 2019 Apr; 14(4):e1800340. PubMed ID: 30315690
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.
Gahoual R; Biacchi M; Chicher J; Kuhn L; Hammann P; Beck A; Leize-Wagner E; François YN
MAbs; 2014; 6(6):1464-73. PubMed ID: 25484058
[TBL] [Abstract][Full Text] [Related]
13. Comparison of originator and biosimilar therapeutic monoclonal antibodies using comprehensive two-dimensional liquid chromatography coupled with time-of-flight mass spectrometry.
Sorensen M; Harmes DC; Stoll DR; Staples GO; Fekete S; Guillarme D; Beck A
MAbs; 2016 Oct; 8(7):1224-1234. PubMed ID: 27362833
[TBL] [Abstract][Full Text] [Related]
14. Rapid charge variant analysis of monoclonal antibodies to support lead candidate biopharmaceutical development.
Trappe A; Füssl F; Carillo S; Zaborowska I; Meleady P; Bones J
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Sep; 1095():166-176. PubMed ID: 30077097
[TBL] [Abstract][Full Text] [Related]
15. Modulation of high mannose levels in N-linked glycosylation through cell culture process conditions to increase antibody-dependent cell-mediated cytotoxicity activity for an antibody biosimilar.
Rameez S; Gowtham YK; Nayar G; Mostafa SS
Biotechnol Prog; 2021 Sep; 37(5):e3176. PubMed ID: 34021724
[TBL] [Abstract][Full Text] [Related]
16. Titer and charge-based heterogeneity multiattribute monitoring of mAbs in cell culture harvest using 2D ProA CEX MS.
Sarin D; Kumar S; Rathore AS
Talanta; 2024 Aug; 276():126232. PubMed ID: 38749159
[TBL] [Abstract][Full Text] [Related]
17. Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community.
Markus R; Liu J; Ramchandani M; Landa D; Born T; Kaur P
BioDrugs; 2017 Jun; 31(3):175-187. PubMed ID: 28439817
[TBL] [Abstract][Full Text] [Related]
18. [Structural characterization and analysis of Omalizumab and its biosimilar CMAB007 by LC-MS].
Xu J; Zhang D; Wang H; Guo H
Sheng Wu Gong Cheng Xue Bao; 2016 Apr; 32(4):497-506. PubMed ID: 28853271
[TBL] [Abstract][Full Text] [Related]
19. Mass spectrometric glycoform profiling of the innovator and biosimilar erythropoietin and darbepoetin by LC/ESI-MS.
Harazono A; Hashii N; Kuribayashi R; Nakazawa S; Kawasaki N
J Pharm Biomed Anal; 2013 Sep; 83():65-74. PubMed ID: 23708432
[TBL] [Abstract][Full Text] [Related]
20. In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate.
Chen L; Wang L; Shion H; Yu C; Yu YQ; Zhu L; Li M; Chen W; Gao K
MAbs; 2016 Oct; 8(7):1210-1223. PubMed ID: 27380163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
